

T: 0131-244 2528 0131-244 2375  
E: irene.fazakerley@scotland.gsi.gov.uk  
29 January 2013

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

Dear Healthcare Professional,

**DRUG ALERT CLASS 3 NO 3 – IMMEDIATE FOR ACTION**

Please see the attached drug alert for onward transmission as below.  
Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**  
Finance, e-Health and Pharmaceuticals Directorate

Safeguarding public health  
Defective Medicines Report Centre  
151 Buckingham Palace Road  
London  
SW1W 9SZ  
Telephone +44 (0)20 3080 6574

**MHRA**

## **DRUG ALERT**

### **CLASS 3 MEDICINES RECALL**

**Action Within 5 Days**  
**PHARMACY LEVEL RECALL**

Date: 29 January 2013

EL (13)A/03

Our Ref: MDR 53-01/13

Dear Healthcare Professional,

### **Marlborough Pharmaceuticals Ltd**

#### **Nonoxinol-9**

#### **Gygel Contraceptive Jelly**

**PL 23138/0010**

| Batch Number | Expiry Date | Pack Size | First Distributed |
|--------------|-------------|-----------|-------------------|
| 1135170      | Jun 2013    | 30g       | 31 Mar 2012       |

Marlborough Pharmaceuticals Ltd is recalling the above batch as a precaution because the results of assays carried out on one of the preservatives during routine stability studies did not comply with the required specification. Preservative efficacy tests carried out on this batch at the same time point complied with the Ph. Eur. specification so this finding is not expected to pose a risk to patient safety.

Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit. For enquiries relating to stock returns please contact UDG Credit Claims at [udgcreditclaims@udg.co.uk](mailto:udgcreditclaims@udg.co.uk)

For medical information enquiries please contact 01748 828 789 (24 hour)

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant clinics and to General Practitioners and Community Pharmacists for information.

Yours faithfully

Alison Bunce

Pharmaceutical Assessor, DMRC

#### **MHRA Distribution:**

Regional Contacts for NHS Trusts and Provider Units

Chief Pharmacists: England, Scotland, Wales, Northern Ireland

Prison Health Policy Unit (DH)

Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar

Special Hospitals

Healthcare Commission for distribution to Independent Health Care Establishments

Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency (MHRA)  
151 Buckingham Palace Road London SW1W 9SZ UK  
T 020 3080 6000 [www.mhra.gov.uk](http://www.mhra.gov.uk)

An executive agency of the Department of Health